Inclusion Criteria:

• * Study participant willing and able to provide informed consent
• * Negative urine pregnancy test at baseline for females of childbearing potential
• * Established diagnosis of sarcoidosis by ATS/ERS/WASOG 1999 Statement on of Sarcoidosis
• * Presence of interstitial lung disease by Scadding Stage IV chest radiograph or extensive fibrosis on chest computed tomography
• * Right heart catheterization within six months of baseline visit showing precapillary pulmonary hypertension (mPAP ≥ 25 mmHg, PCWP ≤ 15 mmHg, and PVR \> 3 WU)
• * Patient on stable sarcoidosis therapy for at least three months prior to screening
• * If patients are on oral PAH therapy (PDE5i/SCGS and/or ERA) then dose should be stable for at least three months prior to screening
• * A 6MWT within three months of screening visit of \> 100 meters

Exclusion Criteria:

• * Pregnant patients or those who are actively lactating
• * Patient not willing to use form of birth control (if applicable) during the study
• * Inability to undergo 6MWT, RHC, PFTs or CMRI
• * Predicted survival \< 6 months
• * Patient on any prostanoid or prostanoid analog therapy
• * Patients with left sided heart disease as defined by either a PCWP \> 15 mmHg and/or left ventricular ejection fraction \< 40%
• * Use of any investigational drug/device, or participation in any investigational study with therapeutic intent within 30 days prior to randomization.